Sign In
Buy ABCL
$5.72
-0.410 (-6.69%)
At Close: Jun 03, 2026
AbCellera CEO on effectiveness of Covid-19 anitbody treatment
03:55pm, Wednesday, 13'th Jan 2021
AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.
Andreas Halvorsen Jumps Into 2 New Biotech Companies
05:24pm, Tuesday, 22'nd Dec 2020
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a P
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
IPO Stock Madness Moves to Biotech as AbCellera, Certara Soar
05:58pm, Friday, 11'th Dec 2020
Hot initial public offerings aren't just for technology companies.
Certara, AbCellera Lead Flurry of Health-Care IPOs
12:36pm, Friday, 11'th Dec 2020
Four companies increased the size of their deals.
AbCellera Announces Pricing of Initial Public Offering
10:47pm, Thursday, 10'th Dec 2020
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.
AbCellera Biologics Proposes $357 Million IPO Terms
07:13pm, Monday, 07'th Dec 2020
AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.
